Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease.
Crohn's disease
Monocyte chemoattractant protein-1 (MCP-1)
Predictor
Ustekinumab
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
21
12
2022
received:
04
09
2022
accepted:
18
01
2023
medline:
19
6
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Ustekinumab has been proven to be effective for treatment of patients with Crohn's disease; however, 30-40% of patients have been reported to lose clinical response within 2 years. We aimed to evaluate the efficacy of ustekinumab and identify predictors of short-term and long-term efficacy in Crohn's disease. Patients with Crohn's disease receiving their first ustekinumab infusion in our hospital between June 2017 and September 2020 were prospectively enrolled. Concentrations of serum cytokines and chemokines were measured using a multiplex bead array assay. Fifty-nine Crohn's disease patients were enrolled in this study. Among 34 clinically active patients, 38.2% achieved a clinical response at week 8. None of the assayed factors were associated with short-term clinical response. Cumulative persistence rates of ustekinumab were 77.6% at 1 year and 58.9% at 2 years. Univariate Cox regression analysis revealed that Harvey-Bradshaw Index scores at baseline, concomitant immunomodulator treatment, and concentrations of interferon gamma-induced protein-10, monocyte chemoattractant protein-1 (MCP-1), and interleukin (IL)-1RA, IL-4, IL-6, and IL-8 were significantly associated with loss of efficacy. Multivariate Cox regression analysis found that biologic naïve status (hazard ratio [HR]: 0.1191, 95% confidence interval [CI]: 0.02458-0.5774) and MCP-1 concentrations (HR: 1.038, 95% CI: 1.015-1.062) were significantly and associated with loss of sustained efficacy for ustekinumab treatment. Our findings suggest that pretreatment serum MCP-1 analysis, combined with a history of biologic use, could be a novel biomarker for predicting the long-term efficacy of ustekinumab in patients with Crohn's disease.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Ustekinumab has been proven to be effective for treatment of patients with Crohn's disease; however, 30-40% of patients have been reported to lose clinical response within 2 years. We aimed to evaluate the efficacy of ustekinumab and identify predictors of short-term and long-term efficacy in Crohn's disease.
METHODS
METHODS
Patients with Crohn's disease receiving their first ustekinumab infusion in our hospital between June 2017 and September 2020 were prospectively enrolled. Concentrations of serum cytokines and chemokines were measured using a multiplex bead array assay.
RESULTS
RESULTS
Fifty-nine Crohn's disease patients were enrolled in this study. Among 34 clinically active patients, 38.2% achieved a clinical response at week 8. None of the assayed factors were associated with short-term clinical response. Cumulative persistence rates of ustekinumab were 77.6% at 1 year and 58.9% at 2 years. Univariate Cox regression analysis revealed that Harvey-Bradshaw Index scores at baseline, concomitant immunomodulator treatment, and concentrations of interferon gamma-induced protein-10, monocyte chemoattractant protein-1 (MCP-1), and interleukin (IL)-1RA, IL-4, IL-6, and IL-8 were significantly associated with loss of efficacy. Multivariate Cox regression analysis found that biologic naïve status (hazard ratio [HR]: 0.1191, 95% confidence interval [CI]: 0.02458-0.5774) and MCP-1 concentrations (HR: 1.038, 95% CI: 1.015-1.062) were significantly and associated with loss of sustained efficacy for ustekinumab treatment.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that pretreatment serum MCP-1 analysis, combined with a history of biologic use, could be a novel biomarker for predicting the long-term efficacy of ustekinumab in patients with Crohn's disease.
Substances chimiques
Ustekinumab
FU77B4U5Z0
Chemokine CCL2
0
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
910-920Subventions
Organisme : KAKENHI
ID : 19K17472
Informations de copyright
© 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet 2017; 389: 1741-1755.
Frolkis AD, Lipton DS, Fiest KM et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am. J. Gastroenterol. 2014; 109: 1739-1748.
Ahmed T, Rieder F, Fiocchi C, Achkar JP. Pathogenesis of postoperative recurrence in Crohn's disease. Gut 2011; 60: 553-562.
Limketkai BN, Parian AM, Shah ND, Colombel JF. Short bowel syndrome and intestinal failure in Crohn's disease. Inflamm. Bowel Dis. 2016; 22: 1209-1218.
Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 79-85.
Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat. Rev. Gastroenterol. Hepatol. 2015; 12: 537-545.
Tsai L, Ma C, Dulai PS et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: A meta-analysis of population-based cohorts. Clin. Gastroenterol. Hepatol. 2021; 19: 2031-2045.
Colombel JF, D'Haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: A systematic review. J. Crohns Colitis 2020; 14: 254-266.
Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017; 390: 2779-2789.
Turner D, Ricciuto A, Lewis A et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570-1583.
Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis. Am. J. Gastroenterol. 2011; 106: 644-659 quiz 660.
Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. J. Crohns Colitis 2012; 6: 143-153.
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: Definition, epidemiology, and management. Clin. Transl. Gastroenterol. 2016; 7: e135.
Wendling D, Prati C. Paradoxical effects of anti-TNF-alpha agents in inflammatory diseases. Expert Rev. Clin. Immunol. 2014; 10: 159-169.
Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun. Rev. 2014; 13: 15-19.
Benson JM, Peritt D, Scallon BJ et al. Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011; 3: 535-545.
Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2016; 375: 1946-1960.
Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012; 367: 1519-1528.
Sandborn WJ, Rebuck R, Wang Y et al. Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: The IM-UNITI trial. Clin. Gastroenterol. Hepatol. 2022; 20: 578-590.
Flamant M, Roblin X. Inflammatory bowel disease: Towards a personalized medicine. Therap. Adv. Gastroenterol. 2018; 11: 1756283X17745029.
Yao T, Matsui T, Hiwatashi N. Crohn's disease in Japan: Diagnostic criteria and epidemiology. Dis. Colon Rectum 2000; 43: S85-S93.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006; 55: 749-753.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.
Straatmijer T, Biemans VBC, Hoentjen F et al. Ustekinumab for Crohn's disease: Two-year results of the initiative on crohn and colitis (ICC) registry, a nationwide prospective observational cohort study. J. Crohns Colitis 2021.
Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian real-world study of treatment persistence of ustekinumab in Crohn's disease. Biol. Theory 2021; 15: 237-245.
Monin L, Dubois S, Reenaers C et al. Ustekinumab in bio-naive and bio-failure Crohn's disease patients: Results from a << real-life >> monocentric cohort. Dig. Liver Dis. 2021; 53: 72-78.
Greenup AJ, Rosenfeld G, Bressler B. Ustekinumab use in Crohn's disease: A Canadian tertiary care centre experience. Scand. J. Gastroenterol. 2017; 52: 1354-1359.
Cibor D, Szczeklik K, Koziol K, Pocztar H, Mach T, Owczarek D. Serum concentration of selected biochemical markers of endothelial dysfunction and inflammation in patients with the varying activity of inflammatory bowel disease. Pol. Arch. Intern. Med. 2020; 130: 598-606.
Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009; 29: 313-326.
Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999; 10: 61-86.
Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 2003; 199: 28-35.
Herfarth H, Goke M, Hellerbrand C et al. Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int. J. Colorectal Dis. 2003; 18: 401-405.
Puleston J, Cooper M, Murch S et al. A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2005; 21: 109-120.
Motomura Y, Khan WI, El-Sharkawy RT et al. Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1. Gut 2006; 55: 662-670.
Khan WI, Motomura Y, Wang H et al. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 291: G803-G811.
Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am. J. Gastroenterol. 2011; 106: 1889-1897.
Gaiani F, Rotoli BM, Ferrari F et al. Monocytes from infliximab-resistant patients with Crohn's disease exhibit a disordered cytokine profile. Sci. Rep. 2020; 10: 12238.
Murate K, Maeda K, Nakamura M et al. Endoscopic activity and serum TNF-alpha level at baseline are associated with clinical response to ustekinumab in Crohn's disease patients. Inflamm. Bowel Dis. 2020; 26: 1669-1681.
Caviglia GP, Rosso C, Stalla F et al. On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory Bowel diseases. J. Clin. Med. 2020; 9: 800.
Nishioka K, Ogino H, Chinen T et al. Mucosal IL23A expression predicts the response to ustekinumab in inflammatory bowel disease. J. Gastroenterol. 2021; 56: 976-987.